| By Grace Zhang, Asia Manufacturing journalist |
| Friday, 09 May 2008 |
 |
|
Beijing Double-Crane Pharmaceutical Co., Ltd. (DCPC), a giant in injection production, has entered into an agreement with the Xiangkou Industrial Park in Wuhan’s Hannan district, to build an injection production facility in the park. |
|
|
The RMB 300 million (approx. US$42.9 million), 133 thousand square meter facility will be the largest injection production project in Central China. Its eight production lines will be established using advanced technologies imported from Germany in two phases, with the first phase to reach production-level capacity in early 2009. Upon completion in 2010, the facility will post an annual output of RMB 1 billion (approx. US$ 143 million) in value. |
|
|
DCPC is a renowned pharmaceutical company in and out of China, having entered the market 11 years ago. The investment in Wuhan was mainly designed for production of more than 200 injections. The facility is expected have a big market, as injections are in high demand across the healthcare sector, while to date Central China had been lacking a large production source, according to a director at DCPC. |
|
In addition, the facility will also bring about direct social benefits by creating more than 1,000 jobs once it is put into operation, said an official at the administration of Xiangkou Street where the industrial park is based. Hannan is already home to biopharmaceutical companies. DCPC’s advent will further complement the production capabilities of the area, making it an important pharmaceutical production base in Central China. |
|
|
